November 30, 2017 08:49 AM EST
Deals
Pharma

Af­ter all the love and mon­ey, an­a­lysts spec­u­late that J&J may swoop in with a buy­out of­fer for Gen­mab

John Carroll

Editor & Founder

Gen­mab Chief Ex­ec­u­tive Jan van de Winkel doesn’t un­der­state his af­fec­tion for J&J. When the two com­pa­nies tied the knot over Darza­lex, the CEO de­scribed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times